Table 3. Exposure to Tumor Necrosis Factor Inhibitors Within the Study Population.
| Variable | No. (%) | |
|---|---|---|
| Control participants | Patients | |
| Included patients | 106 | 106 |
| Exposure to TNF inhibitors | 42 (40) | 64 (60) |
| Recent exposure of patients at index date | ||
| <3 mo | NA | 52 (84) |
| <1 y | NA | 56 (90) |
| Missing data | NA | 2 (2) |
| Cumulative duration of TNF inhibitor exposure at index date, median (IQR), y | 3.3 (1.0-5.6) | 2.1 (0.9-5.9) |
| Missing data | 1 (1) | 9 (9) |
| TNF inhibitors used | ||
| Adalimumab | 21 (20) | 35 (33) |
| Infliximab | 20 (19) | 28 (26) |
| Etanercept | 16 (15) | 29 (27) |
| Certrolizumab | 1 (1) | 3 (3) |
| Gomalimumab | 1 (1) | 0 |
Abbreviations: IQR, interquartile range; NA, not applicable; TNF, tumor necrosis factor.